glp-1 agonists tirzepatide gip/glp 1-agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes GLP1 agonists: current and future

We recommend consulting your OB-GYN along with our providers

adults 70% of whom count as overweight or obese fully 12% are estimated to have used GLP-1s, and many lose 10% or more of their body weight when they do

This streamlined process eliminates the need for patients to visit a pharmacy and simplifies access to this important medication

This inflammation contributes to insulin resistance, cardiovascular damage, joint deterioration, cognitive impairment, and accelerated aging

The improvement in pharmacokinetics helped prevent the negative gastrointestinal side effects typical of GLP- 1-based selective agonists by reducing maximum drug exposure and reducing reliance on GLP- 1-mediated pharmacology

Eur J Obstet Gynecol Reprod Biol 142:5356